Literature DB >> 6500583

Influence of fusion cell ratio and cell plating density on production of human-human hybridomas secreting anti-DNA autoantibodies from patients with systemic lupus erythematosus.

H Massicotte, J Rauch, Y Shoenfeld, H Tannenbaum.   

Abstract

The utilization of one human lymphoblastoid cell line in fusion experiments with peripheral blood lymphocytes from patients with systemic lupus erythematosus (SLE) has made it possible to define efficient and reproducible conditions for the production of anti-DNA-secreting human-human hybridomas. This investigation, using the human lymphoblastoid cell line GM 4672 fused in the presence of 44% polyethylene glycol with lymphocytes from SLE patients, demonstrated a maximal yield of 22.8% hybridomas, 17% of which produced anti-DNA antibodies. We were able to define, in two independent laboratories, that the maximal yield of hybridomas occurred when the lymphocyte to GM 4672 cell ratio was 1:1 and cells were seeded in 2.0 ml wells at a concentration of 4 X 10(5) cells/well. This report demonstrates the reproducibility of human-human hybridoma production with the GM 4672 cell line and the establishment of efficient conditions for the production of anti-DNA autoantibodies from SLE patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6500583     DOI: 10.1089/hyb.1984.3.215

Source DB:  PubMed          Journal:  Hybridoma        ISSN: 0272-457X


  3 in total

1.  Monospecific but not polyreactive human hybridoma rheumatoid factors exhibit preferential binding specificities for IgG3 and IgG4.

Authors:  M M Newkirk; J Rauch
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

2.  Human-human hybridoma autoantibodies with both anti-DNA and rheumatoid factor activities.

Authors:  J Rauch; H Tannenbaum; K Straaton; H Massicotte; J Wild
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

Review 3.  Hybridoma technology: new developments of practical interest.

Authors:  S R Samoilovich; C B Dugan; A J Macario
Journal:  J Immunol Methods       Date:  1987-08-03       Impact factor: 2.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.